Cellular Biomedicine Group Inc (NASDAQ:CBMG) has received a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $32.00.
A number of equities research analysts recently weighed in on CBMG shares. Robert W. Baird started coverage on Cellular Biomedicine Group in a report on Wednesday, February 6th. They issued an “outperform” rating and a $26.00 price target on the stock. BidaskClub cut Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a report on Friday, March 15th.
CBMG traded down $0.27 on Friday, hitting $16.86. 34,379 shares of the company traded hands, compared to its average volume of 47,497. The company has a market cap of $299.20 million, a PE ratio of -8.26 and a beta of 2.81. Cellular Biomedicine Group has a 12-month low of $12.04 and a 12-month high of $25.00.
Cellular Biomedicine Group (NASDAQ:CBMG) last released its earnings results on Tuesday, February 19th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.01). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%. Analysts predict that Cellular Biomedicine Group will post -2.09 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in CBMG. BNP Paribas Arbitrage SA grew its holdings in Cellular Biomedicine Group by 1,641.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 2,315 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in Cellular Biomedicine Group by 1,235.7% during the 4th quarter. Meeder Asset Management Inc. now owns 3,446 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 3,188 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in Cellular Biomedicine Group during the 4th quarter valued at $81,000. MetLife Investment Advisors LLC acquired a new stake in Cellular Biomedicine Group during the 4th quarter valued at $110,000. Finally, Wells Fargo & Company MN grew its holdings in Cellular Biomedicine Group by 84.6% during the 1st quarter. Wells Fargo & Company MN now owns 10,451 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 4,789 shares during the last quarter. Hedge funds and other institutional investors own 11.36% of the company’s stock.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
See Also: Bear Market – How and Why They Occur
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.